Twice-daily subcutaneous injection of kisspeptin-54 does not abolish menstrual cyclicity in healthy female volunteers.

Jayasena CN, Comninos AN, Nijher GM, Abbara A, De Silva A, Veldhuis JD, Ratnasabapathy R, Izzi-Engbeaya C, Lim A, Patel DA, Ghatei MA, Bloom SR, Dhillo WS

The Journal of clinical endocrinology and metabolism12 Sept 2013Cited by 22 (Europe PMC)

PMID24030945PMCIDPMC4111853DOI10.1210/jc.2013-1069PepBankPUB-24030945

Read at source PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In healthy women, menstrual cyclicity persisted in all women after follicular-phase kisspeptin‑54 treatment.
In plain wordsIn healthy women, menstrual cycles continued in all women after a week of kisspeptin‑54.
Peptide
Kisspeptin-54 (metastin)
Outcome
No significant changeMenstrual cyclicity
Study
n = 5
Comparator
0.9% saline
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
6.4 nmol/kg twice daily · subcutaneous · menstrual days 7-14As given in this study (human).
Source sentences
Summary
Menstrual cyclicity persisted in all women after follicular-phase kisspeptin-54 treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a prospective, single-blinded, 1-way crossover study. Healthy women received twice-daily sc injections of kisspeptin (6.4 nmol/kg) or 0.9% saline during menstrual days 7-14 (n = 5 per treatment arm). Serial assessments of basal reproductive hormones, ultrasound parameters, LH pulsatilit…
Report a problemFND-2403094501
02HumanNon-randomized trialEfficacy outcome
In healthy women, chronic kisspeptin‑54 exposure did not abolish the acute LH stimulation after kisspeptin‑54 injection.
In plain wordsIn healthy women, a week of kisspeptin‑54 did not stop LH from rising after another kisspeptin‑54 injection.
Peptide
Kisspeptin-54 (metastin)
Outcome
No significant changeLH response to kisspeptin-54 injection after chronic exposure
Study
n = 5
Comparator
0.9% saline
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
6.4 nmol/kg twice daily · subcutaneous · menstrual days 7-14As given in this study (human).
Source sentences
Summary
Chronic exposure to kisspeptin-54 did not abolish acute stimulation of LH after injection of kisspeptin-54 or GnRH.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a prospective, single-blinded, 1-way crossover study. Healthy women received twice-daily sc injections of kisspeptin (6.4 nmol/kg) or 0.9% saline during menstrual days 7-14 (n = 5 per treatment arm). Serial assessments of basal reproductive hormones, ultrasound parameters, LH pulsatilit…
Report a problemFND-2403094502
03HumanNon-randomized trialEfficacy outcome
In healthy women, chronic kisspeptin‑54 exposure did not abolish the acute LH stimulation after GnRH injection.
In plain wordsIn healthy women, a week of kisspeptin‑54 did not stop LH from rising after a GnRH injection.
Peptide
Kisspeptin-54 (metastin)
Outcome
No significant changeLH response to GnRH injection after chronic exposure
Study
n = 5
Comparator
0.9% saline
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
6.4 nmol/kg twice daily · subcutaneous · menstrual days 7-14As given in this study (human).
Source sentences
Summary
Chronic exposure to kisspeptin-54 did not abolish acute stimulation of LH after injection of kisspeptin-54 or GnRH.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a prospective, single-blinded, 1-way crossover study. Healthy women received twice-daily sc injections of kisspeptin (6.4 nmol/kg) or 0.9% saline during menstrual days 7-14 (n = 5 per treatment arm). Serial assessments of basal reproductive hormones, ultrasound parameters, LH pulsatilit…
Report a problemFND-2403094503
04HumanNon-randomized trialEfficacy outcome
In healthy women, kisspeptin‑54 treatment was associated with a shorter mean menstrual cycle than saline.
In plain wordsIn healthy women, kisspeptin‑54 was linked to a shorter menstrual cycle than saline.
Peptide
Kisspeptin-54 (metastin)
Outcome
DecreaseMean menstrual cycle length
Study
n = 5
Comparator
0.9% saline
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
6.4 nmol/kg twice daily · subcutaneous · menstrual days 7-14As given in this study (human).
Measurements
Mean cycle length
26.8 days
kisspeptin
Mean cycle length
28.6 days
saline
Source sentences
Summary
In addition, kisspeptin-54 treatment was associated with a shorter mean length of the menstrual cycle (mean length of menstrual cycle was 28.6 ± 1.4 days with saline vs 26.8 ± 3.1 days with kisspeptin, P < .01)
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a prospective, single-blinded, 1-way crossover study. Healthy women received twice-daily sc injections of kisspeptin (6.4 nmol/kg) or 0.9% saline during menstrual days 7-14 (n = 5 per treatment arm). Serial assessments of basal reproductive hormones, ultrasound parameters, LH pulsatilit…
Report a problemFND-2403094504
05HumanNon-randomized trialEfficacy outcome
In healthy women, kisspeptin‑54 treatment was associated with earlier onset of the highest recorded serum LH than saline.
In plain wordsIn healthy women, kisspeptin‑54 was linked to an earlier LH peak than saline.
Peptide
Kisspeptin-54 (metastin)
Outcome
DecreaseMenstrual day of highest serum LH
Study
n = 5
Comparator
0.9% saline
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
6.4 nmol/kg twice daily · subcutaneous · menstrual days 7-14As given in this study (human).
Measurements
Mean menstrual day of highest LH
13 day
kisspeptin
Mean menstrual day of highest LH
15.2 day
saline
Source sentences
Summary
earlier onset of highest recorded serum LH (mean menstrual day of highest LH was 15.2 ± 1.3 with saline vs 13.0 ± 1.9 with kisspeptin, P < .05)
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a prospective, single-blinded, 1-way crossover study. Healthy women received twice-daily sc injections of kisspeptin (6.4 nmol/kg) or 0.9% saline during menstrual days 7-14 (n = 5 per treatment arm). Serial assessments of basal reproductive hormones, ultrasound parameters, LH pulsatilit…
Report a problemFND-2403094505
06HumanNon-randomized trialEfficacy outcome
In healthy women, kisspeptin‑54 treatment was associated with earlier onset of the luteal phase than saline.
In plain wordsIn healthy women, kisspeptin‑54 was linked to an earlier start of the luteal phase than saline.
Peptide
Kisspeptin-54 (metastin)
Outcome
DecreaseMenstrual day of progesterone increase
Study
n = 5
Comparator
0.9% saline
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
6.4 nmol/kg twice daily · subcutaneous · menstrual days 7-14As given in this study (human).
Measurements
Mean menstrual day of progesterone increase
15.8 day
kisspeptin
Mean menstrual day of progesterone increase
18 day
saline
Source sentences
Summary
earlier onset of the luteal phase (mean menstrual day of progesterone increase was 18.0 ± 2.1 with saline vs 15.8 ± 0.9 with kisspeptin, P < .05).
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a prospective, single-blinded, 1-way crossover study. Healthy women received twice-daily sc injections of kisspeptin (6.4 nmol/kg) or 0.9% saline during menstrual days 7-14 (n = 5 per treatment arm). Serial assessments of basal reproductive hormones, ultrasound parameters, LH pulsatilit…
Report a problemFND-2403094506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.